Find a Clinical Trial

Showing 81 - 90 of 175 Trials

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT04726241

Population:

Pediatrics/Adult

Phase:

II

This study is called a screening study and the purpose of this study to find better ways to diagnose and treat leukemia that has come back after treatment or difficult to treat. Bone marrow, blood, and medical information about cancer and treatment will be collected. The results from this screening study may give other information about leukemia that is important when deciding how to best treat leukemia. Are you Eligible? (Inclusion Criteria) Patients must be 21 years of age or younger Patient must have one of the following: A. Patient has known or suspected relapsed/refractory (including...
Pembrolizumab in combination with gemcitabine for previously treated mycosis fungoides and Sezary syndrome: efficacy and characterization of immune response

Principal Investigator:

Larisa J Geskin, MD

Contact Number:

212-342-5162

NCT Number:

NCT04960618

Population:

Adult

Phase:

II

Primary objective: Determine preliminary clinical effectiveness of pembrolizumab plus gemcitabine in previously treated MF and SS with overall response rate (ORR) using the composite global response criteria including: radiological imaging (PET/CT scans), flow cytometry and mSWAT assessments. 2. Secondary objectives: a. To estimate duration of response (DOR) of pembrolizumab plus gemcitabine in previously treated MF and SS. b. To estimate progression-free survival (PFS) pembrolizumab plus gemcitabine in previously treated MF and SS. c. To estimate overall survival (OS) of patients with...
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis A COG Groupwide Phase 2 Study

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT05828069

Population:

Pediatrics/Adult

Phase:

II

This trial is an open-label, multi-center Phase 2 study to evaluate the safety and efficacy of the pan-RAF inhibitor DAY101 in patients with relapsed/refractory LCH. The primary aim is to determine overall response rate for children and young adults with relapsed or refractory LCH treated with tovorafenib (DAY101) after 2 cycles and must be maintained 4 weeks later. Are you Eligible? (Inclusion Criteria) Age at diagnosis: 180 days- <22 years (at time of study enrollment) -Patients with multifocal progressive, relapsed, or recurrent LCH with measurable disease at study entry -Patients must...
Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated

Principal Investigator:

Catherine Shu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06667076

Population:

Adult

Phase:

II

The purpose of this study is to understand more about the combination of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) who have a specific mutation in the EGFR (epidermal growth factor receptor) gene and have not had prior treatment for their disease. The Food and Drug Administration (FDA) has not approved the combination of amivantamab subcutaneous (given as an injection under the skin) and lazertinib. Are you Eligible? (Inclusion Criteria) must be 18 years old or older - must not be currently enrolled in another investigational study - must agree to use sun protection...
Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder: HCRN GU22-598

Principal Investigator:

Alexander Z. Wei, MD

Contact Number:

212-342-5162

NCT Number:

NCT06809140

Population:

Adult

Phase:

II

The purpose of this study is to see if the combination of enfortumab vedotin and pembrolizumab leads to no detectable cancer on early assessments of the bladder after initial treatment. We are asking you to take part in this research study because you have muscle-invasive bladder cancer. This combination of enfortumab vedotin and pembrolizumab has been tested in people and is approved by the U.S. Food and Drug Administration (FDA) to treat patients with bladder cancer that has spread outside of the bladder (also known as metastatic bladder cancer).Enfortumab vedotin and Pembrolizumab are not...
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT05890352

Population:

Adult

Phase:

II

The purpose of this study is to compare the usual treatment alone to using tazemetostat or zanubrutinib plus the usual treatment for patients with relapsed or refractory large b-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment. Refractory means the LBCL did not respond to earlier treatment. The addition of tazemetostat or zanubrutinib to the usual treatment could shrink the cancer or extend your time without cancer symptoms coming back. But it may also cause side effects, which the doctors will monitor. This study will help the study doctors find out...
Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma

Principal Investigator:

Mary R. Welch, MD, MS

Contact Number:

212-342-5162

NCT Number:

NCT06325683

Population:

Adult

Phase:

II

The purpose of this study is to compare the usual treatment to using the study drugs, relatlimab and nivolumab in patients with recurrent brain cancer. The use of the study drugs, relatlimab and nivolumab, could shrink or stabilize your cancer. But, they could also cause side effects, which the study team will be monitoring. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drugs increase the life of patients compared to the usual...
Randomized double blind phase 2 trial of baby exemestaneversus baby tamoxifen in post-menopausal women at highrisk for breast cancer.BabyTEARS (Baby Tamoxifen or Exemestane AssessmentRandomized Study)

Principal Investigator:

Katherine D Crew, MD

Contact Number:

212-342-5162

NCT Number:

NCT06364267

Population:

Adult

Phase:

II

This study wants to find out if a low dose of BabytamTamoxifen (called Babytam) works better than a low dose of Babyexe Exemestane (called Babyexe) in helping with physical problems like joint pain. We will check this using a special questionnaire about menopause symptoms after 12 months of treatment. This questionnaire is a trusted way to see how menopause or low estrogen affects women, and how these medicines might change those symptoms. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of the investigational drugs, to learn whether...
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis System as an interventional therapy for the treatment of CTCL (Mycosis Fungoides) in patients with TMN classification stage IA, IB or IIA, an open-label,

Principal Investigator:

Larisa J Geskin, MD

Contact Number:

212-342-5162

NCT Number:

NCT05680558

Population:

Adult

Phase:

II

To assess the efficacy of the UVAR® THERAKOS® CELLEX Photopheresis System to treat early stage (IA, IB or IIA) cutaneous T-cell lymphoma (CTCL) using the modified skin-weighted assessment tool (mSWAT) to determine overall response. Are you Eligible? (Inclusion Criteria) This study will include patients who have the diagnosis of Mycosis Fungoides (including confirmatory biopsy) and are over the age of 18. Patients must have the appropriate staging (IA, IB or IIA) and be refractory to at least one of the standard therapies used to treat Mycosis Fungoides. Patients must not be on any...
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT03972657

Population:

Adult

Phase:

I/II

The purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness of REGN5678 which will be given alone first and then be given in combination with cemiplimab. Neither REGN5678 nor Cemiplimab is FDA approved to treat your type of cancer. Cemiplimab is approved by the FDA for the treatment of certain types of metastatic cutaneous squamous cell carcinoma (CSCC) (one of the main types of skin cancer ) or locally advanced CSCC (who are not candidates for curative surgery or curative radiation). REGN5678 has not yet been studied in people. Are...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages